We’re building a pipeline of targeted therapeutics and therapy-guiding tests to address unmet need in immune-driven illnesses. Our unique understanding of patient biology, coupled with our approach to therapeutics and therapy-guiding tests, enables us to rapidly deliver potentially life-changing therapies to patients in need.
- Rheumatoid Arthritis
- Other Inflammatory
We acquire and aggregate omics and health record data from a range of patients with a specific disease.
We analyze omics and health record data using our proprietary AI and machine learning platform to identify biologically distinct patient subgroups.
We match the pharmacology of possible therapies to the biology of each patient subgroup.
There is an urgent need for new therapies to treat immune-driven critical and chronic illnesses such as sepsis, acute respiratory distress syndrome (ARDS) and rheumatoid arthritis.
We believe our precision-firstTM therapeutic approach has the potential to have meaningful and immediate patient impact.
Liu et al. Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts.
JAMA. 2014; 312(1):90–92. DOI:10.1001/jama.2014.5804
Rubenfeld et al. Hospital Volume and the Outcomes of Mechanical Ventilation.
NEJM. 2006; 355:41-50. DOI: 10.1056/NEJMsa053993
Sung et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-249. DOI: 10.3322/caac.21660
Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.